9 Results for "

HER2-overexpressing cells

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "HER2-overexpressing cells" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-14674
CAS No.: 383432-38-0
Purity:  98.72%
Research Areas:  

Infection Cancer

CP-724714 is an orally active and selective HER2 tyrosine kinase inhibitor with an IC50 of 10 nM. CP-724714 inhibits HER2 receptor autophosphorylation and blocks the downstream Ras-Raf-Mek-Erk signaling pathway, thereby inducing cell cycle arrest and apoptosis in tumor cells. CP-724714 exhibits antiviral activity and inhibits various porcine diarrheal coronaviruses, including SADS-CoV (IC50 of 0.91 μM). CP-724714 is an inhibitor of the hepatic transport receptors OATP1B1/MDR1/BSEP, and can enter hepatocytes via active uptake and trigger the accumulation of drugs and bile acids within hepatocytes. CP-724714 can be used in research related to HER2-overexpressing breast cancer and porcine diarrheal coronavirus infection .
loading...
    loading...
Cat. No.: HY-P991588
CAS No.: 2851060-90-5
Synonyms: AC101

Target:  

EGFR Apoptosis

Research Areas:  

Cancer

HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
loading...
    loading...
Cat. No.: HY-P1997
CAS No.: 34787-28-5
Synonyms: Desferrichrome; DFC; N-Desferriferrichrome
Target:  

JNK Apoptosis

Research Areas:  

Infection Cancer

Ferrichrome Iron-free (Desferrichrome; DFC; N-Desferriferrichrome) is the ligand form of iron-loaded Ferrichrome when it is not bound to Fe 3+. Ferrichrome Iron-free induces apoptosis in gastric cancer cells by activating the JNK-DDIT3 apoptotic axis. As an iron chelator, Ferrichrome Iron-free enables dual-modal imaging of HER2 via conjugation with SiR and Trastuzumab (HY-P9907). Ferrichrome Iron-free can be used in the research of gastric cancer and HER2-overexpressing cancers .
loading...
    loading...
Cat. No.: HY-158828
Target:  

EGFR

Research Areas:  

Cancer

SSO111 sodium, a 20mer fully modified antisense oligonucleotide, targets the oncogene?HER2. SSO111 sodium induces exon 15 skipping during splicing, leading to the generation of a novel mRNA transcript that excludes exon 15. SSO111 sodium downregulated HER2 mRNA, which resulted in the inhibition of proliferation and induction of apoptosis in HER2-overexpressing tumor cells.
loading...
    loading...
Cat. No.: HY-183741
CAS No.: 3080226-63-4
Target:  

PI3K Akt

Research Areas:  

Cancer

VVD-844 is an orally active covalent inhibitor of PI3Kα, which inhibits Pl3Kα/p110α interaction with an IC50 of 4 nM. VVD-844 covalently binds to Cys 242 in the RAS binding domain of p110α, blocking RAS-p110α interaction and inhibiting PI3Kα activity. VVD-844 inhibits PI3Kα signaling activation in HER2-overexpressing cells via a RAS-independent mechanism. VVD-844 suppresses tumor growth in mouse. VVD-844 can be used for the research of cancers .
loading...
    loading...
Cat. No.: HY-P991977
Synonyms: 5G9

Target:  

EGFR Apoptosis PARP Akt ERK

Research Areas:  

Cancer

BSI-001 (5G9) is a HER2-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of HER2-positive breast cancer and HER2-overexpressing gastric cancer .
loading...
    loading...
Cat. No.: HY-14674A
CAS No.: 543681-31-8
Research Areas:  

Infection Cancer

CP-724714 succinate is an orally active and selective HER2 tyrosine kinase inhibitor with an IC50 of 10 nM. CP-724714 succinate inhibits HER2 receptor autophosphorylation and blocks the downstream Ras-Raf-Mek-Erk signaling pathway, thereby inducing cell cycle arrest and apoptosis in tumor cells. CP-724714 succinate exhibits antiviral activity and inhibits various porcine diarrheal coronaviruses, including SADS-CoV (IC50 of 0.91 μM). CP-724714 succinate is an inhibitor of the hepatic transport receptors OATP1B1/MDR1/BSEP, and can enter hepatocytes via active uptake and trigger the accumulation of drugs and bile acids within hepatocytes. CP-724714 succinate can be used in research related to HER2-overexpressing breast cancer and porcine diarrheal coronavirus infection .
loading...
    loading...
Cat. No.: HY-185205
CAS No.: 3055745-21-3
Target:  

PI3K Akt

Research Areas:  

Cancer

VVD-484 is a PI3K p110α inhibitor with an IC50 of 0.59 μM against human targets.,VVD-484, classified as a "silent ligand", forms a covalent bond with Cys242 of PI3K p110α without disrupting the p110α-KRAS G12C interaction. VVD-484 inhibits phosphorylation (S473) of AKT via a RAS-independent pathway. VVD-484 can be used in the research of HER2-overexpressing cancers .
loading...
    loading...
Cat. No.: HY-185718
Trastuzumab-DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab (HY-P9907) with DM4 (sulfo-SPDB-DM4) (HY-101141) via a cleavable linker. DM4 is a tubulin inhibitor that suppresses cell division. Trastuzumab-DM4 significantly inhibits tumor growth in Trastuzumab-resistant HER2 xenograft tumor models. Trastuzumab-DM4 can be used for the research of HER2-positive breast cancer .
loading...
    loading...